AI Is No Longer a Technology Question. It Is a Regulatory Evidence Question.

The FDA can now see trial endpoints in real time. NICE recommended Imfinzi 17 days after MHRA approval. The evidence chain is compressing from both ends.

But underneath that acceleration, something else is happening. AI is no longer just supporting drug development. It is generating the evidence that regulators evaluate — patient selection, endpoint analysis, manufacturing quality, submission preparation.

The closer AI moves to a regulatory decision, the higher the credibility bar. The FDA’s 2025 draft guidance made this explicit: what matters is not whether AI is being used, but what decision the AI output supports. The EMA’s reflection paper says the same thing from the European side.

This 25-minute class covers where AI sits in the medicines lifecycle, why context of use determines regulatory significance, and what every regulatory affairs professional needs to understand before their next dossier lands on an assessor’s desk.

The question is no longer whether AI is being used. It is whether the evidence it produces can survive regulatory scrutiny.